Primary resistance to PD-1 blockade mediated by JAK1/2 mutations

Loss of function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned they may also be involved in primary resistance to anti-PD-1 therapy. JAK1/2 inactivating mutations were noted in tumor biopsies of 1 of 23 patients with melanoma and i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Discov
Glavni autori: Shin, Daniel Sanghoon, Zaretsky, Jesse M., Escuin-Ordinas, Helena, Garcia-Diaz, Angel, Hu-Lieskovan, Siwen, Kalbasi, Anusha, Grasso, Catherine S., Hugo, Willy, Sandoval, Salemiz, Torrejon, Davis Y., Palaskas, Nicolaos, Rodriguez, Gabriel Abril, Parisi, Giulia, Azhdam, Ariel, Chmielowski, Bartosz, Cherry, Grace, Seja, Elizabeth, Berent-Maoz, Beata, Shintaku, I. Peter, Le, Dung Thi, Pardoll, Drew M., Diaz, Luis A., Tumeh, Paul C., Graeber, Thomas G., Lo, Roger S., Comin-Anduix, Begoña, Ribas, Antoni
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5296316/
https://ncbi.nlm.nih.gov/pubmed/27903500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1223
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items